Nothing Special   »   [go: up one dir, main page]

MX2012013274A - Novedosos derivados de la pirimidina. - Google Patents

Novedosos derivados de la pirimidina.

Info

Publication number
MX2012013274A
MX2012013274A MX2012013274A MX2012013274A MX2012013274A MX 2012013274 A MX2012013274 A MX 2012013274A MX 2012013274 A MX2012013274 A MX 2012013274A MX 2012013274 A MX2012013274 A MX 2012013274A MX 2012013274 A MX2012013274 A MX 2012013274A
Authority
MX
Mexico
Prior art keywords
sup
pyrimidine derivatives
novel pyrimidine
compounds
methods
Prior art date
Application number
MX2012013274A
Other languages
English (en)
Inventor
Marita Hoegberg
Tommy Johansson
Emma Dahlstedt
Olof Smitt
Original Assignee
Chemilia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10163597A external-priority patent/EP2395001A1/en
Application filed by Chemilia Ab filed Critical Chemilia Ab
Publication of MX2012013274A publication Critical patent/MX2012013274A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona novedosos derivados de la pirimidina de fórmula I, métodos de preparación de estos compuestos, composiciones farmacéuticas que contienen dichos compuestos y métodos para el uso de dichos compuestos en el tratamiento de enfermedades, incluyendo el cáncer (Ver Formula) en donde R1, R2, R3, R4, R5, L, A, D, E, Z, y Y son como se definen en la especificación.
MX2012013274A 2010-05-21 2011-05-20 Novedosos derivados de la pirimidina. MX2012013274A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10163597A EP2395001A1 (en) 2010-05-21 2010-05-21 Novel pyrimidine derivatives
EP10187289 2010-10-12
PCT/EP2011/058271 WO2011144742A1 (en) 2010-05-21 2011-05-20 Novel pyrimidine derivatives

Publications (1)

Publication Number Publication Date
MX2012013274A true MX2012013274A (es) 2013-05-28

Family

ID=44084010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013274A MX2012013274A (es) 2010-05-21 2011-05-20 Novedosos derivados de la pirimidina.

Country Status (13)

Country Link
US (1) US8927547B2 (es)
EP (1) EP2571867B1 (es)
JP (1) JP5607241B2 (es)
KR (1) KR20130031296A (es)
CN (1) CN103003264B (es)
AU (1) AU2011254550B2 (es)
BR (1) BR112012029647A2 (es)
CA (1) CA2798578C (es)
IL (1) IL222867A0 (es)
MX (1) MX2012013274A (es)
RU (1) RU2528386C2 (es)
WO (1) WO2011144742A1 (es)
ZA (1) ZA201209029B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103002738A (zh) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 用于激酶调节的化学化合物、组合物和方法
AU2012230229A1 (en) * 2011-03-24 2013-10-10 Noviga Research Ab Novel pyrimidine derivatives
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104011050A (zh) * 2011-12-22 2014-08-27 霍夫曼-拉罗奇有限公司 作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
EP2711364A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
EP2711365A1 (en) 2012-09-21 2014-03-26 Chemilia AB 4-Indazolylamino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TW201534597A (zh) * 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2016205304A1 (en) * 2015-06-16 2016-12-22 Signal Pharmaceuticals, Llc Methods of treatment using substituted diaminopyrimidyl compounds
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210988A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as pge2 receptor modulators
MX2019013639A (es) 2017-05-18 2020-01-21 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos.
CN110612296A (zh) 2017-05-18 2019-12-24 爱杜西亚药品有限公司 作为pge2受体调节剂的苯基衍生物
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
EP4242203A1 (en) * 2020-11-06 2023-09-13 Pelemed Co., Ltd. Novel capsid assembly inhibitor
WO2022199561A1 (zh) * 2021-03-23 2022-09-29 杭州阿诺生物医药科技有限公司 Hpk1激酶抑制剂化合物

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226413B1 (en) 1991-06-25 2008-11-28 Aventis Pharma Sa Novel 16-(nitro-substituted methyl)pregna-1,4-dien-3,20-dion derivatives and process for producing them
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5491234A (en) 1992-03-30 1996-02-13 Pfizer Inc. Pyrimidine derivatives for enhancing antitumor activity
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
DK1169038T3 (da) 1999-04-15 2012-11-26 Bristol Myers Squibb Co Cykliske proteintyrosinkinaseinhibitorer
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
DE10007411A1 (de) 2000-02-18 2001-08-23 Bayer Ag Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2006201264A1 (en) 2000-09-15 2006-04-27 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
AU2006201262B2 (en) 2000-09-15 2008-09-04 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
AU2006201265B2 (en) 2000-09-15 2008-09-04 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
WO2002022606A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2006201263B2 (en) 2000-09-15 2008-10-30 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful As Protein Kinase Inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2006201230B8 (en) 2000-09-15 2008-09-25 Vertex Pharmaceuticals Incorporated Triazole Compounds Useful As Protein Kinase Inhibitors
EP2264028A1 (en) 2000-12-21 2010-12-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DE60138645D1 (de) 2000-12-21 2009-06-18 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
AU2006201229B2 (en) 2000-12-21 2008-11-20 Vertex Pharmaceuticals Incorporated Pyrazole Compounds Useful as Protein Kinase Inhibitors
AU2002231139B2 (en) 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
WO2002096888A1 (de) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
KR20100107509A (ko) 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
AU2006252047B2 (en) 2001-09-14 2010-02-11 Methylgene Inc. Inhibitors of histone deacetylase
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026664A1 (en) 2001-09-26 2003-04-03 Bayer Corporation 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
DK1438053T3 (da) 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
PT1442024E (pt) 2001-11-01 2008-06-12 Janssen Pharmaceutica Nv Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b)
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP2005524668A (ja) 2002-03-01 2005-08-18 スミスクライン ビーチャム コーポレーション ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
DE60314603T2 (de) 2002-03-15 2008-02-28 Vertex Pharmaceuticals Inc., Cambridge Zusammensetzungen brauchbar als protein-kinase-inhibitoren
AU2003231231A1 (en) 2002-05-06 2003-11-11 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
RU2310651C2 (ru) 2002-08-30 2007-11-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, фармацевтическая композиция, их содержащая, способ лечения и применение
US20040209930A1 (en) 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
WO2004041164A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Kinase inhibitors
AU2003288198A1 (en) 2002-11-28 2004-06-18 Schering Aktiengesellschaft CHK-,PDK- and AKT-inhibitory pyrimidines, their production and use as pharmaceutical agents
PL379330A1 (pl) 2002-12-20 2006-08-21 Pfizer Products Inc. Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ATE433447T1 (de) 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
PL1658292T3 (pl) 2003-07-16 2008-01-31 Janssen Pharmaceutica Nv Pochodne triazolopirymidyny jako inhibitory kinazy 3 syntazy glikogenu
ES2317031T3 (es) 2003-07-16 2009-04-16 Janssen Pharmaceutica Nv Derivados de triazolopirimidina como inhibidores de la glucogeno-sintasa-quinasa 3.
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
CA2534921C (en) 2003-08-06 2011-06-14 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US20050113398A1 (en) 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
DK1660458T3 (da) 2003-08-15 2012-05-07 Irm Llc 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
US7767806B2 (en) 2003-09-08 2010-08-03 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid modification products and drug carriers using them
JP4205543B2 (ja) 2003-09-09 2009-01-07 本田技研工業株式会社 小型船
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
JP2007505858A (ja) 2003-09-18 2007-03-15 ノバルティス アクチエンゲゼルシャフト 増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
TW200526253A (en) 2003-11-14 2005-08-16 Chugai Pharmaceutical Co Ltd Cross-linked polysaccharide microparticles and process for producing the same
JP5160788B2 (ja) 2003-11-24 2013-03-13 プロメティック、バイオサイエンシーズ、インコーポレーテッド 化合物、その化合物を含む組成物、その化合物を利用した自己免疫疾患の治療方法
JP2007514775A (ja) 2003-12-19 2007-06-07 ライジェル ファーマシューティカルズ， インコーポレイテッド １−（２，４−ピリミジンジアミノ）−２−シクロペンタンカルボキサイミド合成中間体の立体異性体および立体異性体混合物
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
ATE485824T1 (de) 2004-04-13 2010-11-15 Icagen Inc Polycyclische pyrimidine als kaliumionenkanal- modulatoren
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
US20060205945A1 (en) 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7754714B2 (en) 2004-05-18 2010-07-13 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
WO2006012502A2 (en) 2004-07-23 2006-02-02 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US7521457B2 (en) 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
US20060058525A1 (en) 2004-09-01 2006-03-16 Rajinder Singh Synthesis of 2,4-pyrimidinediamine compounds
JP5060131B2 (ja) 2004-09-07 2012-10-31 中外製薬株式会社 水溶性ヒアルロン酸修飾物の製造方法
US7971443B2 (en) 2004-10-28 2011-07-05 Sharp Kabushiki Kaisha Refrigerator
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
JP2008534689A (ja) 2005-04-05 2008-08-28 ファーマコペイア， インコーポレイテッド 免疫抑制のためのプリン及びイミダゾピリジン誘導体
DE102005016634A1 (de) 2005-04-12 2006-10-19 Merck Patent Gmbh Neuartige Aza-Hetercyclen als Kinase-Inhibitoren
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2614678A1 (en) 2005-07-08 2007-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Ligands of melanocortin receptors
BRPI0613452A2 (pt) 2005-07-11 2011-01-11 Sanofi Aventis derivados de 2,4-dianilino pirimidinas, o respectivo preparo, a tìtulo de medicamentos, composições farmacêuticas e notadamente como inibidores de ikk
WO2007014198A1 (en) 2005-07-25 2007-02-01 Synta Pharmaceuticals Corp. 1, 2, 3 -triazoles inhibitors of tubulin polymerization for the treatment of poliferative disorders
US7486280B2 (en) 2005-08-04 2009-02-03 Uniplas Enterprises Pte, Ltd. Contoured capacitive touch control panel
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
US20090118310A1 (en) 2005-08-09 2009-05-07 University Of Medicine And Dentistry Of New Jersey Activated Cdc42-associated kinase (ACK) as a therapeutic target for Ras-induced cancer
JP2009511548A (ja) 2005-10-14 2009-03-19 ノイロサーチ アクティーゼルスカブ 新規ピリミジン−２，４−ジアミン誘導体及び小コンダクタンスのカルシウム依存性カリウムチャネルのモジュレーターとしてのこれらの使用
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
EP1959961A2 (en) 2005-12-06 2008-08-27 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
BRPI0620324A2 (pt) 2005-12-21 2011-11-08 Pfizer Prod Inc derivados de pirimidina, composição farmaceutica e uso dos mesmos
US7962290B1 (en) 2006-01-09 2011-06-14 Rigel Pharmaceuticals, Inc. Identification of pharmacophores from co-crystals of spleen tyrosine kinase (SYK) and SYK ligands
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CA2648170A1 (en) 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
CN101058561B (zh) 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
EP2020231A4 (en) 2006-04-26 2010-11-10 Ito En Ltd FAT ABSORPTION INHIBITORS
US20080082567A1 (en) 2006-05-01 2008-04-03 Bezanson Jeffrey W Apparatuses, Methods And Systems For Vector Operations And Storage In Matrix Models
US7956185B2 (en) 2006-05-26 2011-06-07 Abbott Laboratories Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinases
US7460807B2 (en) 2006-05-31 2008-12-02 Kabushiki Kaisha Toshiba Image forming apparatus and method of controlling the apparatus
JP2009540013A (ja) 2006-06-15 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アニリノ−４−（複素環）アミノ−ピリミジン
EP2044063A1 (en) 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
WO2008005538A2 (en) 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
DE102006041382A1 (de) 2006-08-29 2008-03-20 Bayer Schering Pharma Ag Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren
KR101451290B1 (ko) 2006-10-19 2014-10-15 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
US20080119496A1 (en) 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
RS53588B1 (en) 2006-12-08 2015-02-27 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
CA2672893C (en) 2006-12-15 2016-02-23 Abraxis Bioscience, Inc. Triazine derivatives and their therapeutical applications
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
AU2007337088A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Pyrimidine kinase inhibitors
EP1939185A1 (de) 2006-12-20 2008-07-02 Bayer Schering Pharma Aktiengesellschaft Neuartige Hetaryl-Phenylendiamin-Pyrimidine als Proteinkinaseinhibitoren zur Behandlung von Krebs
EP2134713A2 (en) 2006-12-20 2009-12-23 Schering Corporation Novel jnk inhibitors
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
US20080214558A1 (en) 2007-03-01 2008-09-04 Supergen, Inc. Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors
CN103588704B (zh) 2007-03-16 2016-09-14 斯克里普斯研究学院 粘着斑激酶抑制剂
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
KR101424847B1 (ko) 2007-04-16 2016-07-08 허치슨 메디파르마 엔터프라이즈 리미티드 피리미딘 유도체
CN101289444B (zh) 2007-04-16 2012-01-04 和记黄埔医药（上海）有限公司 一种嘧啶衍生物及其医药用途
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
US20090012045A1 (en) 2007-06-26 2009-01-08 Rigel Pharmaceuticals, Inc. Methods of Treating Cell Proliferative Disorders
CN101796046A (zh) 2007-07-16 2010-08-04 阿斯利康(瑞典)有限公司 嘧啶衍生物934
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
JP2010538004A (ja) 2007-08-28 2010-12-09 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての２−ビフェニルアミノ−４−アミノピリミジン誘導体
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2920996A1 (en) 2007-10-19 2009-04-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
EA019869B1 (ru) 2007-11-28 2014-06-30 Дана Фарбер Кансер Инститьют, Инк. Низкомолекулярные миристатные ингибиторы тирозинкиназы bcr-abl и способы их применения
US20090142832A1 (en) 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
JP2011505407A (ja) 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 過剰な又は異常な細胞増殖を特徴とする疾患を治療するためのジアミノピリジン
ES2610880T3 (es) 2008-02-22 2017-05-03 Rigel Pharmaceuticals, Inc. Uso de 2,4-pirimidinadiaminas para el tratamiento de la aterosclerosis
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
CA2726508C (en) 2008-06-17 2016-06-07 Astrazeneca Ab Pyridine compounds
US8445505B2 (en) 2008-06-25 2013-05-21 Irm Llc Pyrimidine derivatives as kinase inhibitors
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CN101684098A (zh) 2008-09-24 2010-03-31 中国科学院上海药物研究所 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用
EP2241555A1 (en) * 2009-04-14 2010-10-20 Universita' Degli Studi Di Milano New RAC1 inhibitors as potential pharmacological agents for heart failure treatment
JP2013523657A (ja) 2010-03-26 2013-06-17 グラクソ グループ リミテッド キナーゼ阻害剤としてのインダゾリル‐ピリミジン
EP2552214A4 (en) 2010-03-26 2013-10-16 Glaxo Group Ltd PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
JP2012209902A (ja) 2011-03-30 2012-10-25 Semiconductor Components Industries Llc 入出力回路

Also Published As

Publication number Publication date
US8927547B2 (en) 2015-01-06
JP5607241B2 (ja) 2014-10-15
RU2012155712A (ru) 2014-06-27
RU2528386C2 (ru) 2014-09-20
AU2011254550B2 (en) 2013-11-07
ZA201209029B (en) 2014-02-26
BR112012029647A2 (pt) 2016-08-02
KR20130031296A (ko) 2013-03-28
US20130089518A1 (en) 2013-04-11
EP2571867A1 (en) 2013-03-27
CN103003264B (zh) 2014-08-06
CA2798578A1 (en) 2011-11-24
IL222867A0 (en) 2012-12-31
CA2798578C (en) 2015-12-29
AU2011254550A1 (en) 2012-12-20
EP2571867B1 (en) 2015-11-04
WO2011144742A1 (en) 2011-11-24
JP2013526562A (ja) 2013-06-24
CN103003264A (zh) 2013-03-27

Similar Documents

Publication Publication Date Title
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MX2020002924A (es) Lactamas fusionadas de arilo y heteroarilo.
MX2014012695A (es) Derivados de isoindolona.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
EA201390381A1 (ru) Триазиноксадиазолы
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
MX343706B (es) Derivados heterocíclicos novedosos.
IN2015DN01119A (es)
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
IN2014MN02598A (es)
IN2012DN03182A (es)
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2012DN02139A (es)
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
WO2013040227A3 (en) Therapeutic compounds
MX360330B (es) Regimen de administracion para nitrocatecoles.
IN2012DN01292A (es)
MY152018A (en) Indole derivatives as anticancer agents

Legal Events

Date Code Title Description
FG Grant or registration